Servier and CTI BioPharma are expanding their existing license and development collaboration agreement for lymphoma treatment Pixuvri.
Servier will have rights to Pixuvri (pixantrone) in all markets except the US, where CTI BioPharma will retain the commercialisation privileges.
Servier will pay CTI BioPharma €12 million with the potential for CTI BioPharma to receive €76 million in additional sales and regulatory milestone payments as well as royalties on net product sales.
Pixuvri has been granted conditional marketing authorisation from the European Commission for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (NHL).
As a specific post-authorisation requirement, Pixuvri is currently being investigated in a Phase III clinical trial, PIX306. If positive, the results from this trial will confirm the treatment’s current indication and could support broader indications.
In 2014, CTI granted Servier rights to commercialise the drug globally except in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, UK and the US.
With this expanded agreement, which provides Servier’s rights to all markets except the US, the companies will continue to work closely together to build the efficacy and safety evidence for Pixuvri and to ensure that as many eligible patients as possible are benefitting from it.
“Over the past three years, we have worked hand in hand with our partner, CTI BioPharma, to bring new treatment options to patients in Europe,” said U. Marion Schrenk, MD, Head of Therapeutic Area Oncology of Servier.
She added: “We are looking forward to leveraging our expertise in these additional markets to ensure more eligible patients have access to Pixuvri.”
Image credit: Shutterstock.com/ photo4passion.at